Rosuvastatin calcium in acute coronary syndromes.

INTRODUCTION

Low-density lipoprotein cholesterol (LDL-C) reduction using 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) has a proven survival benefit in patients presenting with acute coronary syndromes (ACS). Patients presenting with ACS remain at significant risk of subsequent cardiovascular death and non-fatal myocardial infarction despite high compliance with current guideline indicated secondary prevention therapies. There remains, therefore, a need to consider the potential benefits of more intensive LDL-C lowering after presentation with ACS. Rosuvastatin is the most potent of the currently available statins and has some unique pharmacological properties that may be advantageous in such patients.

AREAS COVERED

We conducted a Medline literature search to identify rosuvastatin papers and papers on statin use in ACS published in English. In this review, we outline the pharmacology of rosuvastatin and examine its efficacy and safety. We also evaluate the published trials of statin therapy in ACS and offer an opinion on the use of rosuvastatin in ACS.

EXPERT OPINION

There is adequate clinical trial evidence confirming the LDL-C lowering efficacy and safety of high-dose rosuvastatin in ACS. Whilst there are sound theoretical reasons to consider early use of high-dose rosuvastatin in ACS, the available level of evidence is insufficient to justify a wholesale change from the current standard of care.